GKWIM
URGN icon

Gerber Kawasaki Wealth & Investment Management’s UroGen Pharma URGN Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8
Closed – – 1062
2021
Q3 		$0 Buy
+8
New +$127 ﹤0.01% 1235

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's URGN Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of UroGen Pharma (URGN) in Q4 2021, closing a stake of 8 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in URGN in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 78 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining UroGen Pharma position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 8 UroGen Pharma shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in UroGen Pharma in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's UroGen Pharma position peaked at $0 in Q3 2021.
  • 78 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.